List of Excipients in Branded Drug ZEJULA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	ZEJULA	niraparib	0173-0909	CELLULOSE, MICROCRYSTALLINE	2039-01-25
GlaxoSmithKline LLC	ZEJULA	niraparib	0173-0909	CROSPOVIDONE	2039-01-25
GlaxoSmithKline LLC	ZEJULA	niraparib	0173-0909	LACTOSE MONOHYDRATE	2039-01-25
GlaxoSmithKline LLC	ZEJULA	niraparib	0173-0909	MAGNESIUM STEARATE	2039-01-25
GlaxoSmithKline LLC	ZEJULA	niraparib	0173-0909	POVIDONE	2039-01-25
GlaxoSmithKline LLC	ZEJULA	niraparib	0173-0909	SILICON DIOXIDE	2039-01-25
GlaxoSmithKline LLC	ZEJULA	niraparib	0173-0909	WATER	2039-01-25

Zejula Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Zejula is an immediate-release oral capsule containing niraparib tosylate monohydrate. Its commercial formulation uses a conventional powder-fill excipient system: lactose monohydrate, crospovidone, magnesium stearate, and colloidal silicon dioxide, with a gelatin capsule shell.[1] The strongest opportunities are generic capsule development, differentiated lactose-free products, additional strengths, supply-chain optimization, and formulation improvements that support adherence without changing the approved route or release profile.

The core commercial constraint is that excipient innovation does not by itself avoid compound, method-of-use, or regulatory exclusivity barriers. A successful competitor must combine an acceptable formulation with an ANDA strategy, bioequivalence evidence, patent certification, and reliable access to pharmaceutical-grade niraparib or its salt.

What is Zejula and how is the product formulated?

Zejula is the brand name for niraparib, a poly(ADP-ribose) polymerase, or PARP, inhibitor marketed by GSK. The FDA-approved product is an oral capsule supplied in a 100 mg strength.[1]

Attribute	Zejula profile
Active ingredient	Niraparib tosylate monohydrate
Active moiety	Niraparib
Dosage form	Immediate-release hard gelatin capsule
U.S. strength	100 mg niraparib equivalent per capsule
Primary manufacturer	GSK
Original developer	Tesaro
FDA category	Small-molecule prescription drug
Administration	Oral, with or without food
Principal use	Maintenance treatment in selected ovarian, fallopian tube, and primary peritoneal cancers

The U.S. label identifies the inactive ingredients as lactose monohydrate, crospovidone, magnesium stearate, and colloidal silicon dioxide. The capsule shell contains gelatin and titanium dioxide, with printing components identified in the prescribing information.[1]

The formulation is commercially significant because it is relatively simple. It does not depend on a modified-release matrix, lipid vehicle, complex coating system, or device. That reduces technical barriers for an ANDA applicant but increases the importance of powder-flow control, content uniformity, capsule filling, dissolution, and impurity management.

What excipients are used in Zejula capsules?

Lactose monohydrate

Lactose is the principal diluent and contributes bulk to the capsule fill. It is widely available, inexpensive, and familiar to generic manufacturers. Its disadvantages are equally clear:

• It creates a barrier for patients with lactose intolerance or lactose-avoidance preferences.
• It can create supply and labeling complications in markets with strict allergen or excipient disclosure requirements.
• Its particle-size distribution affects blend uniformity and capsule-fill consistency.
• Its moisture behavior can influence stability and powder flow.

A lactose-free version is the most obvious formulation differentiation strategy. Candidate alternatives include microcrystalline cellulose, mannitol, dibasic calcium phosphate, and selected spray-dried composite excipients. Each substitution requires comparative dissolution, stability, manufacturability, and bioequivalence assessment.

Crospovidone

Crospovidone functions as a superdisintegrant. In an immediate-release capsule, it helps the powder mass disperse after the shell dissolves. Its performance depends on grade, particle size, distribution within the blend, and the degree of agglomeration during processing.

A generic applicant can optimize crospovidone loading, but the commercial benefit is likely to be incremental. The main value is process robustness rather than a strong product claim. Excessive disintegrant can impair powder flow or create segregation risk.

Magnesium stearate

Magnesium stearate is a lubricant used to reduce friction during blending and capsule filling. Its concentration and blending time require control. Over-lubrication can reduce wettability and slow dissolution, while under-lubrication can increase fill-weight variability and equipment fouling.

A low-lubricant or alternative-lubricant strategy may support a more robust dissolution profile, but it must be validated against commercial-scale filling conditions. Potential alternatives include sodium stearyl fumarate or other pharmaceutical lubricants, subject to compatibility and regulatory acceptability.

Colloidal silicon dioxide

Colloidal silicon dioxide improves flow and reduces cohesion in the powder blend. It is particularly relevant if an applicant replaces lactose with a different filler or uses a narrower particle-size distribution.

The main development issue is balance. Too little may produce poor flow and weight variation. Too much can alter bulk density, blend behavior, and capsule-fill performance.

What excipient strategies offer the best commercial opportunity?

Lactose-free Zejula generic

A lactose-free capsule is the clearest patient-facing opportunity. A formulation based on microcrystalline cellulose, mannitol, or a composite filler could support:

• A differentiated inactive-ingredient profile.
• Broader use among patients avoiding lactose.
• Reduced dependence on lactose supply.
• Potential positioning through specialty-pharmacy channels.

The product would still need to meet ANDA requirements. A different excipient system does not remove the need to demonstrate pharmaceutical equivalence and bioequivalence.

Additional capsule strengths

The FDA label uses a weight- and platelet-based dosing approach in certain patients, including a 200 mg starting dose for patients below specified body-weight or platelet thresholds and a 300 mg starting dose for others.[1] A 50 mg capsule could improve dose adjustment, reduce capsule splitting or complex combinations, and support tolerability management.

A 50 mg strength may have greater clinical utility than a new excipient alone. Its commercial value would depend on regulatory pathway, labeling requirements, manufacturing economics, and whether the strength is protected by a listed patent or other exclusivity.

Adherence-oriented packaging

Niraparib treatment is chronic maintenance therapy. Packaging can therefore produce commercial value without changing the formulation. Opportunities include:

• Calendar blister packs.
• Dose-reduction packs.
• Starter packs for titration.
• Specialty-pharmacy packaging.
• Serialization and adherence tracking.

Packaging claims usually provide weaker protection than formulation or process patents, but they can improve dispensing accuracy and patient persistence.

Sprinkle or flexible-administration products

A capsule intended to be opened and sprinkled onto food could address swallowing difficulties. This strategy carries substantial technical and regulatory risk because opening the capsule may affect dose uniformity, stability, handling exposure, and labeling.

A sprinkle product would need evidence addressing:

• Uniform delivery of the full dose.
• Stability after opening.
• Food compatibility.
• Powder handling by caregivers.
• Occupational exposure during preparation.
• Whether the product remains pharmaceutically equivalent.

This is a higher-value but higher-risk opportunity than a conventional lactose-free capsule.

Tablet or multiparticulate reformulation

A tablet could improve automated packaging and manufacturing throughput. It could also enable scoring, smaller units, or a different excipient profile. The commercial case is weaker if the capsule already has acceptable swallowing characteristics and broad market access.

Multiparticulates or coated pellets would be harder to justify for an immediate-release drug unless they solve a defined problem such as dose flexibility, taste, stability, or administration to patients unable to swallow capsules.

How does Zejula’s excipient profile compare with competing PARP inhibitors?

Zejula competes with other oral PARP inhibitors, including Lynparza, Rubraca, and Talzenna. Their commercial formulations differ in active ingredients, strengths, capsule or tablet presentations, and excipient systems.

Product	Active ingredient	Common U.S. dosage forms	Excipient opportunity
Zejula	Niraparib	Immediate-release capsule	Lactose-free capsule, 50 mg strength, adherence packaging
Lynparza	Olaparib	Tablet, historical capsule presentation	Tablet manufacturing and dose flexibility
Rubraca	Rucaparib	Tablet	Alternate tablet excipient systems
Talzenna	Talazoparib	Capsule	Capsule shell, strength, and powder-flow optimization

Zejula’s simple capsule formulation creates a lower technical entry barrier than products with more complex delivery systems. It also limits differentiation. A competing product is unlikely to command a durable premium solely because it changes magnesium stearate level or replaces one conventional filler with another.

The strongest differentiators are likely to be:

1. Lower cost of goods.
2. Consistent supply.
3. A lactose-free formulation.
4. A 50 mg strength.
5. Packaging that supports dose reduction and adherence.
6. A reliable specialty-pharmacy distribution model.

What patents protect Zejula and its formulation?

Zejula exclusivity may arise from several layers:

• Niraparib compound patents.
• Salt or crystal-form patents.
• Formulation patents.
• Manufacturing and purification patents.
• Method-of-use patents.
• Regulatory exclusivity linked to approved indications.

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved drug products.[2] The label’s excipient list does not establish whether an excipient combination is patented. Many conventional excipient systems are difficult to protect broadly because the ingredients are standard pharmaceutical materials.

Formulation patent risk

A formulation patent would present greater risk if it claims a specific combination of:

• Niraparib tosylate particle size.
• Defined dissolution performance.
• A particular excipient ratio.
• A stability advantage.
• A capsule-fill density or manufacturing process.
• A polymorphic or crystalline active form.

An applicant should not assume that a simple formulation is unprotected. Patent claims can focus on process parameters, solid-state characteristics, impurity limits, or performance specifications rather than the ingredient list alone.

Method-of-use patent risk

Niraparib has been approved across ovarian-cancer maintenance settings and patient subgroups. Method-of-use patents can create commercial exposure even after the compound patent expires. A generic applicant may need a Paragraph IV certification, a section viii carve-out, or labeling controls depending on the listed claim and the proposed product’s indication.[2][3]

When does Zejula lose exclusivity?

Zejula does not have a single exclusivity date. Market entry depends on the interaction of:

• Listed U.S. patents.
• Patent-term adjustments and extensions.
• Pediatric exclusivity.
• New indication exclusivity.
• Paragraph IV litigation.
• Settlement agreements.
• The approved generic label.

The original Tesaro development program became part of GSK after GSK acquired Tesaro for approximately $5.1 billion in 2019.[4] GSK’s commercial exposure is therefore concentrated in the branded niraparib franchise and its associated oncology indications.

A generic applicant can seek approval before patent expiry by certifying that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger a 30-month stay of approval if the patent holder files suit within the statutory period.[3]

No biosimilar pathway applies to Zejula. Niraparib is a small molecule, so competitive entry will occur through the ANDA route rather than the 351(k) biosimilar pathway.

Which companies are challenging Zejula?

Generic competition is typically initiated by ANDA applicants that remain confidential until Paragraph IV notice, litigation, or FDA approval becomes public. The FDA Orange Book and federal court records are the principal sources for identifying a named challenger.[2]

The commercial threat should be assessed by category:

Challenger type	Likely strategy	Risk to GSK
First Paragraph IV filer	Seek 180-day exclusivity if eligible	High
Conventional ANDA filer	Enter after patent or litigation resolution	High after settlement or expiry
Authorized generic	Price competition under GSK control	Medium to high
Specialty generic	Different strength or excipient profile	Medium
Foreign manufacturer	Lower-cost supply into regulated markets	Dependent on approval and sourcing

A first generic entrant can sharply compress net pricing even if the branded product retains patients through physician familiarity, specialty-pharmacy support, or indication-specific use.

What is the FDA regulatory status of Zejula?

Zejula is FDA-approved as an oral niraparib product for specified maintenance-treatment indications in advanced ovarian, fallopian tube, and primary peritoneal cancers.[1] The FDA label includes dose modification provisions for hematologic toxicity and patient characteristics.

From an excipient perspective, the key regulatory requirements are:

• Pharmaceutical equivalence to the reference product.
• Bioequivalence under the applicable FDA standard.
• Comparable dissolution.
• Demonstrated stability through the proposed shelf life.
• Control of nitrosamines, elemental impurities, and other relevant contaminants.
• Compliance with inactive-ingredient limits and FDA precedent.
• Validated capsule-filling and content-uniformity processes.

The FDA generally does not approve an excipient change as a commercial advantage by itself. The change must support a product that meets the applicable abbreviated-approval requirements.

What manufacturing and intellectual-property barriers affect generic Zejula?

The main manufacturing barriers are operational rather than exotic:

• Consistent niraparib salt particle size.
• Control of powder segregation.
• Accurate capsule fill weights.
• Low-dose blend uniformity at the 100 mg strength.
• Lubrication control.
• Dissolution reproducibility.
• Protection against moisture and cross-contamination.
• Reliable supply of active pharmaceutical ingredient.

Niraparib is a potent oncology active. Facilities must manage containment, cleaning validation, worker exposure, and segregation from non-potent products. These requirements can increase capital costs and restrict the number of qualified contract manufacturers.

The strongest defensible intellectual-property position for a reformulated product would likely involve a specific technical result, such as improved stability, reduced impurity formation, controlled particle size, or a defined manufacturing process. A generic substitution of lactose with microcrystalline cellulose is commercially useful but may offer limited patent strength.

What licensing deals affect Zejula’s commercial position?

Tesaro originated niraparib development and commercialized Zejula before GSK acquired Tesaro in 2019.[4] The acquisition transferred the product, development program, and related intellectual property into GSK’s oncology portfolio.

For prospective partners, the most relevant licensing questions are:

• Whether GSK licenses regional commercialization rights.
• Whether API supply is tied to a specific manufacturer.
• Whether formulation patents are assigned to GSK or licensed from third parties.
• Whether settlement agreements restrict generic launch timing.
• Whether authorized-generic rights are reserved.

A formulation developer should treat API access and freedom to operate as separate workstreams. A non-infringing excipient system does not solve a blocked API process or compound-patent issue.

What generic launch scenarios exist for Zejula?

Early Paragraph IV entry

This scenario creates the greatest price shock. The first filer may obtain a period of generic exclusivity, while GSK may respond through litigation, settlement, authorized-generic launch, or commercial contracting.

Staggered entry after settlement

A settlement can establish an agreed launch date before the latest patent expiry. The economic effect depends on the number of entrants, any authorized-generic provisions, and whether the settlement contains supply or licensing terms.

Multi-source entry after patent expiry

Several ANDA holders may launch close together. Pricing pressure is then stronger, and excipient differentiation becomes less important than manufacturing cost, supply reliability, and wholesaler access.

Differentiated niche entry

A lactose-free product, 50 mg strength, or specialty packaging configuration could preserve a modest commercial position even after broad generic entry. Such products must remain economically justified after additional development and regulatory costs.

Key Takeaways

• Zejula uses a relatively simple immediate-release capsule formulation based on lactose monohydrate, crospovidone, magnesium stearate, and colloidal silicon dioxide.
• The best excipient opportunity is a lactose-free capsule supported by a robust powder-flow and dissolution package.
• A 50 mg strength may create more clinical and commercial value than a minor excipient substitution.
• A tablet, sprinkle product, or multiparticulate formulation would require a stronger patient or manufacturing rationale.
• Excipients alone are unlikely to provide strong market exclusivity unless linked to defined performance, stability, solid-state, or process claims.
• Zejula is a small molecule and faces generic, not biosimilar, competition.
• Patent, Paragraph IV, and settlement analysis must be based on the live FDA Orange Book and court record.
• GSK’s principal exposure is the erosion of branded niraparib revenue after the first approved generic or authorized generic launch.

FAQs

Can a lactose-free Zejula generic receive FDA approval?

Yes. An ANDA applicant can use different inactive ingredients if the product satisfies FDA pharmaceutical-equivalence, bioequivalence, safety, quality, and labeling requirements.

Is niraparib a BCS Class I or Class III drug?

BCS classification depends on the regulatory jurisdiction, test conditions, and submitted data. A developer should not assume that a formulation change qualifies for a biowaiver without jurisdiction-specific evidence.

Can a generic company sell Zejula in a 50 mg capsule?

Potentially. A 50 mg strength would require FDA approval and must address patent certifications, product labeling, dose proportionality, manufacturing controls, and bioequivalence requirements.

Are Zejula excipients protected by a separate patent?

The ingredient list alone does not establish patent protection. Risk depends on live claims covering composition, particle size, solid form, dissolution, stability, or manufacturing parameters.

Does Zejula require a biosimilar application?

No. Niraparib is a chemically synthesized small molecule. A competing product would generally use the ANDA pathway rather than the FDA biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). Zejula (niraparib) capsules: Prescribing information. GlaxoSmithKline LLC.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2017). Reference listed drug and reference standard database. https://www.fda.gov/drugs

4. GlaxoSmithKline. (2019). GSK completes acquisition of Tesaro, an oncology company. https://www.gsk.com

5. U.S. Food and Drug Administration. (2017). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry.

6. European Medicines Agency. (2023). Zejula: European public assessment report. https://www.ema.europa.eu